Related Experiment Videos
Clinical trials: surrogate endpoints or hard endpoints?
1Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Insights
Detecting subclinical atherosclerosis is key to preventing myocardial infarction and coronary artery disease. Early detection enables personalized prevention strategies and advances understanding of atherosclerosis risk factors.
Area of Science:
- Cardiovascular Medicine
- Preventive Cardiology
- Medical Imaging
Background:
- Lifetime risk of myocardial infarction (MI) is significant, with a 50-year-old man having a 50% risk and a 50-year-old woman a 35% risk.
- The extent of atherosclerosis is the primary determinant of MI risk.
- Substantial reduction in coronary artery disease (CAD) lifetime risk necessitates primary prevention of atherosclerosis.
Purpose of the Study:
- To highlight the importance of noninvasive methods for measuring subclinical atherosclerosis.
- To emphasize the role of subclinical disease in improving patient-specific preventive strategies.
- To underscore the potential for new drug development and understanding of atherosclerosis.
Main Methods:
- Utilizing noninvasive imaging techniques to assess subclinical atherosclerosis.
- Monitoring the progression of subclinical atherosclerosis.
- Analyzing plaque characteristics to understand atherosclerosis development.
Main Results:
- Subclinical atherosclerosis measurement offers a unique opportunity for personalized preventive strategies.
- Pharmacologic and nonpharmacologic therapies can be optimized based on subclinical disease assessment.
- Subclinical disease serves as a surrogate marker for atherosclerosis, aiding in research.
Conclusions:
- Primary prevention of atherosclerosis is crucial for reducing lifetime CAD risk.
- Noninvasive assessment of subclinical atherosclerosis enhances understanding of risk factors, lipoprotein metabolism, and genetic-lifestyle interactions.
- Further research into subclinical disease and plaque characteristics is vital for advancing cardiovascular medicine.
Abstract:
A man, aged 50, has about a 50% risk and a 50-year-old woman a 35% risk of having a myocardial infarction during their lifetime. The extent of atherosclerosis is the primary determinant of the risk of myocardial infarction. We will be unable to substantially reduce the lifetime risk of coronary artery disease without primary prevention of atherosclerosis. Noninvasive methods to measure subclinical atherosclerosis and its progression offer a unique opportunity to improve individual patient preventive strategies, based both on pharmacologic and nonpharmacologic therapies, as well as an opportunity to study and develop new drug therapies. The use of subclinical disease as a surrogate marker of atherosclerosis and the study of plaque characteristics will greatly enhance our understanding of the role of new risk factors for atherosclerosis, lipoprotein metabolism, and genetic-lifestyle interactions.